BioSpace News Archive

OSE Immunotherapeutics SA presents scientific updates in oral and poster presentations selected for international conferences: at the Antibody Engineering & Therapeutics Europe 2023 Conference in Amsterdam, Netherlands, at the FOCIS 2023 Annual Meeting, the 4th Annual Cytokine-Based Drug Development Summit 2023 and at the 3rd Annual Tumor Myeloid-directed Therapies Summit 2023 in Boston, US.

POXEL SA announced its participation at the ULF Scientific Symposium and Family Conference on June 23rd and 24th in Itasca, Illinois, USA.

Mablink Bioscience, a biotechnology company dedicated to advancing cancer therapy with next-generation antibody-drug conjugates, announced the appointment of Dr. Pejvack Motlagh, M.D., as Chief Medical Officer.

With immunotherapy emerging as one of the most important treatment options in oncology, GE HealthCare has announced the first patient scanned in a Phase I clinical trial of a first-of-its kind fluorine-18 PET radiopharmaceutical specific for CD8, which is expressed on CD8+ T cells - a subpopulation of white blood cells which fight cancer.

Astellas Pharma Inc. and Cullgen Inc. announced a research collaboration and exclusive option agreement to discover multiple innovative protein degraders.

BeiGene, a global biotechnology company, announced that it will present data on its Bruton’s tyrosine kinase inhibitor BRUKINSA® at the 17th International Conference on Malignant Lymphoma, which is taking place from June 13-17 in Lugano, Switzerland.

RaySearch Laboratories AB is pleased to announce an agreement with the Chinese radiation therapy machine manufacturer Shinva.

bit.bio, a synthetic biology company focused on human cells, has achieved a milestone in the manufacture of human cells.

ITM Isotope Technologies Munich SE announced that it will host a multidisciplinary symposium titled, “Investing in the Future of Theranostics: Aligning Supply to Clinical Need,” at the Society of Nuclear Medicine and Molecular Imaging Therapeutics Conference, held from June 24-27 in Chicago, Illinois, USA.

Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors, announced that it has entered into a research collaboration with AbCellera for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets.